Dr.Sally Price

Exciting news about B2 supplementation

Riboflavin is the vitamin most people think they understand. It's B2, it turns urine bright yellow, it's in every multivitamin, RDA is 1.3 mg. End of story. There's a piece of biology this framing misses, and it changes what happens when you take a 50 or 100 mg dose.

Two facts have to land together. The first is about you. The second is about your gut bacteria.

The first: riboflavin absorption from a single oral dose maxes out at approximately 27 mg. Zempleni and colleagues established this in 1996 in the American Journal of Clinical Nutrition using pharmacokinetic modeling across 20, 40, and 60 mg oral doses. The transporter responsible, RFVT3, sits on the apical membrane of cells in the jejunum and ileum. It is saturable. Past the ceiling, additional riboflavin does not meaningfully enter the bloodstream. It continues down the gastrointestinal tract.

The second: a major colonic butyrate-producing bacterium called Faecalibacterium prausnitzii cannot make its own riboflavin. Khan and colleagues showed in 2012 that F. prausnitzii uses exogenous riboflavin as an extracellular electron shuttle. The bacterium is an obligate anaerobe, but it lives directly against the gut wall where oxygen leaks from the epithelium. Riboflavin lets it offload electrons from intracellular NADH to that trace oxygen, which allows it to thrive in a position other anaerobes cannot tolerate. The riboflavin has to come from somewhere outside the cell. It does not synthesize it.

Put those together and you get a specific prediction: oral riboflavin doses above the small-intestinal ceiling should reach the colon and increase activity in butyrate-producing bacteria that depend on it.

The RIBOGUT trial tested this. Liu and colleagues, published in Antioxidants & Redox Signaling in 2023, randomized 105 healthy adults to placebo, 50 mg/day, or 100 mg/day of riboflavin for two weeks in a double-blind parallel-group design. The 50 mg group showed a non-significant trend toward higher f***l butyrate. The 100 mg group reached statistical significance on its own. When the two riboflavin groups were pooled, the increase was significant at p = 0.013. The microbial composition barely shifted. The activity did. Same species, more butyrate.

This is the part to sit with. Most microbiome interventions try to change which bacteria are present. This one changed what the bacteria already present were doing.

A few caveats worth naming. The trial was sponsored by DSM Nutritional Products, a major manufacturer of riboflavin. The mechanism work that preceded it (Khan 2012, Zempleni 1996) is independent. The trial was in healthy adults, not in patients with IBD or low baseline F. prausnitzii, which is where this approach would matter clinically. F. prausnitzii is a major butyrate producer but not the only one, and the relative contribution of riboflavin-dependent versus other pathways to total f***l butyrate has not been mapped in humans. The duration was two weeks. Longer studies and patient populations would tighten the picture.

What this changes in practice depends on how you think about B2. If the goal is to fix a clinical deficiency, 1.3 to 5 mg/day is enough. If you have a riboflavin-responsive condition where high doses are standard (migraine prophylaxis uses 400 mg/day), you are already operating well above the absorption ceiling and the colonic delivery is happening whether the protocol intended it or not. The framing most consumers carry, that B2 above the RDA is wasted and ends up in your urine, is half true. The fraction that exceeds 27 mg per dose does not enter your bloodstream. It does not all end up in your urine either. A portion of it ends up in your colon, and there is now human RCT data showing that fraction does measurable work.

Riboflavin is one of the few water-soluble vitamins where the surplus is not just safe at supraphysiological doses but appears to be biologically active in a different compartment from where the labeled function lives. The yellow urine is the visible part. The butyrate is the part that matters.

Zempleni et al., Am J Clin Nutr, 1996

Khan et al., Antioxid Redox Signal, 2012

Liu et al., Antioxid Redox Signal, 2023

UPDATE ON THE BIGGEST VACCINE MANDATE CASE This litigation may impact more than all Australian States